Diag-Nose.io Secures $2 Million in Seed Funding to Revolutionize Precision Medicine in Respiratory Health

We are thrilled to announce that Diag-Nose.io has successfully raised $2,000,000 in a funding round aimed at enhancing our innovative approach to precision diagnostics and drug discovery. Founded in 2020 and headquartered in Melbourne, Australia, Diag-Nose.io has emerged as a pioneering force in the biotechnology sector, dedicated to unraveling the complexities of the unified airway through state-of-the-art scientific methods. Our precision medicine technology merges advanced proteomics, computational biology, and artificial intelligence, specifically machine learning, to develop a scalable model of respiratory biology. This breakthrough not only empowers clinicians to prescribe more effective treatments swiftly but also expedites the entire process of creating new therapeutic solutions. At the heart of our endeavors is RhinoMAP™, our flagship platform that harnesses the power of proteomic data. RhinoMAP™ is designed to predict respiratory disease activity, monitor therapy responses, and evaluate treatment efficacy proactively, with a special emphasis on anti-Th2 biologics as our starting point. The new funding will significantly enhance our research capabilities, allow us to further refine our technology, and ultimately help us deliver more precise and personalized treatment options for patients suffering from respiratory conditions. As we embark on this exciting new chapter, we are deeply grateful for the support of our investors and are eager to drive forward our mission of transforming respiratory health through cutting-edge biotechnology solutions.